In order to further analyze the possible mechanism, we measured the proportion of CD3+CD4+, CD3+CD8+, CD3−CD19+, and CD16+CD56+ cells in peripheral blood of patients with multiple myeloma. This evidence concerns the gene NCAM1 and plasma cell myeloma.